Time to regain birth weight - a marker to predict the severity of retinopathy of prematurity?

Ajay Anvekar1*, Sam Athikarisamy2,3,4, Shripada Rao2,3,4, Andy Gill2,3,4, Elizabeth Nathan5,6, Dorota Doherty5,6 and Geoffrey Lam7,8

Abstract

Background: Poor weight gain in the first few weeks of life has been studied as a predictor of retinopathy of prematurity (ROP). Our aim was to assess whether time taken to regain birthweight (BW) be used as an additional marker to identify infants with type 1 ROP.

Methods: In this retrospective study, preterm infants (< 27 weeks gestational age at birth) born during the period from 1/1/2010–31/12/2015 at a tertiary neonatal intensive care unit in Australia were included. Twenty-seven preterm infants with Type 1 ROP were identified. Controls (No ROP or ROP other than type 1) were matched with cases on gestational age at birth and BW (1:4 ratio). Data were collected from the database and medical records.

Results: The median (IQR) gestational age for Type 1 ROP and control groups were 24 (24–26) and 25 (24–26) weeks respectively and median (IQR) BW for Type 1 ROP and control groups were 675 (635–810) and 773 (666–884) grams respectively. Preterm infants with Type 1 ROP were more likely to be small for gestational age (SGA) (18.5% vs 3.7%, \(p = 0.015\)) and had increased weeks on oxygen therapy (median 11.9 vs 9.1, \(p = 0.028\)). Time to regain BW was longer in preterm infants with type 1 ROP than controls but did not reach statistical significance (median 9 vs 7 days, OR 1.08, 95% CI 1.00–1.17, \(p = 0.059\)) adjusted for SGA and duration of oxygen therapy. The area under the curve from the time to regain BW model with adjustment for SGA and duration of oxygen therapy was 0.73 (95% CI 0.62–0.83).

Conclusion: We hypothesize that time to regain BW has potential to aid prediction of Type 1 ROP and this warrants further investigation in a larger prospective study.

Keywords: Preterm, Birth weight, Retinopathy of prematurity

Background

Retinopathy of prematurity (ROP) is a retinal neovascular disease seen in the low birthweight preterm infants [1]. Severe forms of ROP can lead to retinal detachment and blindness if not identified and treated at the right time [2]. ROP is one of the major causes of childhood blindness, in both developed and developing countries [3]. Improved survival of preterm infants and perinatal services has led to an increased incidence of severe ROP [3].

The aetiopathogenesis is complex and multifactorial. Arrest of the normal retinal vascular development is followed by an abnormal compensatory vascularization which leads to ROP. In phase 1 of ROP development, hyperoxia and loss of growth factors provided in utero to the fetus result in suppression of growth, and arrest of retinal vascularization. Subsequently, in phase
2, hypoxia causes stimulation of growth factor induced vasoproliferation in the increasing metabolically active, poorly vascularized retina [4]. These two phases result from alteration in levels of insulin like growth factor (IGF)-1 and vascular endothelial growth factor (VEGF) [5]. IGF-1 is needed for normal retinal vascularization [6–9] and it also influences VEGF- induced retinal vascular growth [7, 10]. Low IGF-1 following preterm birth due to loss from maternal sources and poor endogenous production [6, 11–13] impedes retinal vessel development. IGF-1 is regulated by calorie and protein intake [14]. Endogenous production of IGF-1 increases with age and size allowing VEGF activity, and proliferative retinopathy develops [15].

Prenatal factors such as premature placental dysfunction increase the risk of ROP in preterm infants following postnatal exposure to risk factors [16]. Low gestational age (GA) [17] and birthweight (BW) [18] are major risk factors for ROP. Excessive supplemental oxygen, sepsis, necrotizing enterocolitis, intraventricular hemorrhage, anemia, apnea, and blood transfusion have been described as risk factors for ROP and have been hypothesized to act by lowering serum IGF-1 levels [15].

The association between low IGF-1 and poor postnatal weight gain in the development of ROP has been shown by the research work of Smith, Hellstrom et al. which have led to the use of postnatal growth as a surrogate measure for serum IGF-1 [19, 20]. Algorithms based on postnatal weight gain (WINROP, CHOP ROP, ROP score) have shown variable sensitivity in detecting infants at risk of developing ROP in different populations. These algorithms have the potential to reduce the number of eye examinations for ROP [15].

The risk of developing ROP has been shown to be associated with poor weight gain in the first few weeks of life. Extreme preterm infants are vulnerable to have low energy intake during their early neonatal intensive course, which has been associated with poor weight gain in the first 4 weeks of life [21]. Suboptimal postnatal weight gain in the first 2 weeks of life has been found to be an independent risk factor for ROP needing treatment.

Screening infants for ROP involves repeated ophthalmologic examinations by trained ophthalmologists, which are not free from adverse event [1]. Pain, stress to infants, hypoxemic and apneic episodes and feed intolerance have been associated with ophthalmic examinations for ROP [22]. Of all the infants undergoing screening, only 10% needed treatment for ROP [23]. Our study aimed to determine whether time taken to regain BW can be used as an early additional marker for identifying infants at risk of developing Type 1 ROP.

Materials and methods

Design and setting

A retrospective case control study in a tertiary level NICU in Australia

Ethics approval

This study was approved by the hospital Governance Committee and the institutional research screening committee.

Participants

All preterm infants (<27 weeks gestational age at birth) admitted between January 2010 and December 2015, were enrolled for analysis. Preterm infants who developed Type 1 ROP and needed treatment were identified. Controls defined as preterm infants who had No ROP or had ROP other than type 1 and hence no treatment. Controls were matched with cases on GA at birth and BW on a 1:4 ratio with equal distribution between no ROP and ROP but not type 1 (Fig. 1). Infants who had congenital anomalies or critical cardiac conditions and who died before developing ROP were excluded from the study.

Data collection

The following data was collected from each infant's medical record and neonatal database using a standardized, pre-piloted data collection form.

Antenatal risk factors: Chorioamnionitis, preeclampsia, diabetes mellitus, oligohydramnios, premature rupture of membrane and antenatal glucocorticoids.

Delivery details: Place of birth, GA, BW, gender, growth status, mode of delivery and Apgar scores.

Post-delivery care: Time to regain BW, duration of mechanical ventilation and noninvasive ventilation, duration of oxygen therapy, treatment for patent ductus arteriosus, necrotizing enterocolitis, postnatal steroids, need for blood transfusion, culture positive sepsis, duration of hospital stay, presence of intraventricular hemorrhage and periventricular leukomalacia on head scans and death before discharge were collected.

Outcomes

The primary outcome was to determine whether the ‘time taken to regain BW’ can be a useful marker in identifying infants who developed Type 1 ROP. The secondary outcomes were to assess the effect of chorioamnionitis, blood transfusion, antenatal steroids, duration of oxygen therapy and culture positive sepsis as risk factors for Type 1 ROP.
**Inclusion criteria**
Preterm infants <27 weeks gestational age at birth
Study period: Jan 2010 – Dec 2015

**Exclusion criteria**
Infant had congenital anomalies or critical cardiac conditions or who died before developing ROP

**Total number of eligible infants from neonatal database:** 258

**Infants with ROP:** 146
1:4 matching on gestational age at birth and birth weight

**Type 1 ROP group:** 27
(Laser = 25, anti VEGF = 2)
Stage I-II: 5
(Treated because of plus disease)
Stage ≥ III: 22
Plus disease: 17

**Control group:** 108
ROP but not type 1 ROP: 54
No ROP: 54
Stage I-II: 44
Stage ≥ III: 10
Plus disease: 1

**Infants with no ROP:** 112

Fig. 1 Study design
Guidelines for management of ROP in the NICU

Screening criteria
Neonates born <31 weeks postmenstrual age, regardless of BW and neonates with BW <1250 g, regardless of postmenstrual age at birth were screened for ROP. Neonates born greater than 31 weeks gestation at birth, BW >1250 g, with additional problems, were screened at the discretion of the treating Neonatologist.

The screening examination for ROP followed the guidelines proposed by American Academy of Pediatrics Section on Ophthalmology; American Academy of Ophthalmology; American Association for Pediatric Ophthalmology and Strabismus and American Association of Certified Orthoptists [24] with amendments from local experience. The first screening examination was performed at 30 to 31 week postmenstrual age in infants born at <27 weeks GA and at 4-5 weeks postnatal age in infants born at 27- to 31-week GA. After the first evaluation, if the subject did not have ROP, the neonate was evaluated at 2–4 week intervals until full vascularization. If the patient had active or rapid progressive lesion, the subject was evaluated more frequently, depending on the clinical findings.

Treatment for ROP in the unit was primarily laser surgery and the treatment decisions were based on the Early Treatment ROP guidelines. Laser was performed for retinal findings of Type 1 ROP (Zone 1 ROP: any stage with plus disease; Zone I ROP: stage 3, no plus disease; and Zone II: stage 2 or 3 with plus disease). Anti VEGF treatment was used for infants who were unwell for laser or if the disease process was posterior and laser was a risk for damaging ocular structures.

Statistical method
Continuous data were summarized with medians, interquartile ranges (IQR) and ranges (R), and categorical data as frequency distributions. Conditional logistic regression analysis was used to univariately compare characteristics between cases and controls, and multivariable modelling to examine the effect of time to regain BW on Type 1 ROP. An assessment of potential confounders including chorioamnionitis, duration of oxygen therapy, blood transfusion, antenatal steroids and culture positive sepsis was made using a forward selection method to avoid over-parameterization. Univariate and adjusted effects were summarized as odds ratios (OR) and adjusted OR (aOR) respectively, with 95% confidence intervals (CI). The predictive potential of time to regain BW for Type 1 ROP was further assessed using area under the curve (AUC) constructed from probabilities generated from the conditional logistic regression models. Time to event data, including duration of continuous positive airway pressure, mechanical ventilation, nasal high flow and oxygen were summarized using Kaplan-Meier survival estimates and compared using the log rank test, with deaths before discharge censored for analysis. IBM SPSS (version 22.0, Armonk, NY) and Cytel Studio (version 8.0, 2007) statistical software were used for data analysis. p-values <0.05 were considered statistically significant.

Results
Twenty seven preterm infants with type 1 ROP [Laser (n=25), Anti VEGF (n=2)] were matched on a 1:4 ratio with 108 controls on GA and BW (Fig. 1). The median (IQR) GA for Type 1 ROP and control groups were 24 (24–26) and 25 (24–26) weeks respectively, and the median (IQR) BW for Type 1 ROP and control groups were 675 (635–810) and 773 (666–884) grams respectively. Preterm infants with type 1 ROP were more likely to be small for gestational age (SGA) (18.5% vs 3.7%, p =0.015) and had increased weeks of oxygen therapy (median 11.9 vs median 9.1, p =0.028). Other demographic and clinical characteristics were similar between the two groups. All in the type 1 ROP group (n=27) and 103/108 (95.4%) controls were given blood transfusions (Table 1). Preterm infants with type 1 ROP had advanced stages of ROP compared to controls (Fig. 1).

Median (IQR) time to regain BW in Type 1 ROP group and controls were 9(6–13) and 7(5–10) days respectively (Table 1, Fig. 2). On univariate analysis, there was no significant association between time to regain BW and the development of Type 1 ROP (OR 1.06, 95% CI 0.99–1.14, p =0.108). The association of time to regain BW for developing type 1 ROP after adjusting for duration of oxygen therapy and SGA did not reach statistical significance (aOR 1.08, 95% CI 1.00–1.17, p =0.059) (Table 2). Other risk factors assessed in the model were not statistically significant (all p-values>0.05, Table 2).

The AUC’s for the individual model covariates were: time to regain BW AUC: 0.60, 95% CI 0.47–0.72, weeks of oxygen therapy AUC: 0.65, 95% CI 0.54–0.77 and SGA AUC: 0.63, 95% CI 0.55–0.72. When time to regain BW was modelled simultaneously with oxygen duration and SGA, the AUC was increased to 0.73, 95% CI 0.62–0.83 demonstrating some predictive potential for Type 1 ROP (Fig. 3).

Discussion
Our analysis of this retrospective data showed that the time to regain BW was longer in infants who needed treatment for ROP but didn’t reach statistical significance. However, AUC from our multivariable model for time to regain BW suggest that it may have the capability to be an additional marker for detecting Type 1 ROP. The possible reason for not reaching significance could be the
Table 1 Demographic and clinical characteristics

|                          | Type 1 ROP (n = 27) | Control (n = 108) | P-value |
|--------------------------|---------------------|-------------------|---------|
| Male                     | 19 (70.4%)          | 61 (56.5%)        | 0.274   |
| Inborn                   | 26 (96.3%)          | 103 (95.4%)       | 1.000   |
| SGA                      | 5 (18.5%)           | 4 (3.7%)          | 0.015   |
| Chorioamnionitis         | 8 (29.6%)           | 20 (18.5%)        | 0.176   |
| Antenatal steroids (complete) | 18 (66.7%)          | 73 (68.9%)        | 0.927   |
| Caesarean section        | 18 (66.7%)          | 49 (45.8%)        | 0.061   |
| Apgar<7 at 1 min         | 25 (92.6%)          | 90 (83.3%)        | 0.366   |
| Apgar<7 at 5 min         | 9 (33.3%)           | 30 (27.8%)        | 0.725   |
| Time to regain birthweight | 9 (6–13)            | 7 (5–10)          | 0.114   |
| PDA treated              | 20 (74.1%)          | 79 (73.1%)        | 1.000   |
| NEC                      | 1 (3.7%)            | 6 (5.6%)          | 1.000   |
| IVH                      | 3 (12.0%)           | 4 (3.8%)          | 0.280   |
| PVL                      | 1 (12.5%)           | 1 (2.7%)          | 0.720   |
| Culture positive sepsis  | 9 (33.3%)           | 28 (25.9%)        | 0.439   |
| Mechanical ventilation (days) | 30.8 (8.5–44.6)    | 11.3 (2.2–34.4)  | 0.191   |
| CPAP (days)              | 44.6 (37.2–55.8)    | 44.8 (35.5–55.7)  | 0.997   |
| Nasal high flow (days)   | 10.0 (0–19.3)       | 11.1 (0–18.8)     | 0.632   |
| Duration of oxygen (weeks) | 11.9 (7.0–17.9)    | 9.1 (4.0–13.4)    | 0.028   |
| Postnatal steroids       | 2 (7.4%)            | 7 (6.5%)          | 1.000   |
| Blood transfusion        | 27 (100%)           | 103 (95.4%)       | 0.622   |
| Oxygen at 36weeks        | 19 (70.4%)          | 64 (59.3%)        | 0.417   |
| Home oxygen              | 3 (11.1%)           | 8 (7.4%)          | 0.763   |
| Died during NICU stay    | –                   | 2 (1.9%)          | 1.000   |

Data represents median (IQR) or number (%). IUGR Intrauterine growth restriction, CPAP Continuous positive airways pressure, PDA Patent ductus arteriosus, NEC Necrotizing enterocolitis, IVH Intraventricular hemorrhage, PVL Periventricular leukomalacia, NICU Neonatal intensive care unit

Fig. 2 Box plot comparing time to regain birthweight on Type 1 ROP
low prevalence of ROP and small sample size. The infants in our study were extreme preterm (≤ 27 weeks PMA at birth) and had very low BW (≤ 1260 g) with preterm infants with type 1 ROP being more SGA than controls.

IGF-1, a peptide and its importance in prenatal, postnatal growth and role in development of retinal vasculature has been studied extensively. Postnatal growth being a good surrogate measure of serum IGF-1 has led to development of surveillance models which use GA, BW and postnatal weight gain to identify infants at risk of developing ROP. These models are limited by their sensitivity, lack of generalizability especially in non-Caucasian populations [25].

Association between postnatal weight gain and severe ROP has been studied by multiple investigators and it is important to discuss these studies. Earlier studies looked at the postnatal growth in the first four to 6 weeks of life and its association with severe ROP. A prospective study of 345 preterm infants by Filho et al. [26] (GA < 32 weeks, BW < 1500 g) found that poor weight gain at 6 weeks of life was a significant risk for ROP (small and appropriate for gestational age groups) and in a different study, Filho et al. [20] concluded that low weight gain by 6 weeks of age was a risk for severe ROP (n = 317). Further support for poor weight gain by 6 weeks of age was a risk for ROP (n = 317). Further support for poor weight gain by 6 weeks of age and risk for severe ROP are supported by studies of Wallace et al. [27], Allegraert et al. [28] and Cabanas Poy [29]. Poor postnatal weight gain in the first 4 weeks of life was significantly associated with ROP needing treatment in a retrospective study of 233 preterm infants. Infants gaining 10g/
day had a risk reduction of 2.76–8.34% vs 7.17–12.76% in infants gaining 20 g/day [30]. Association of poor weight gain in the first 4 weeks with severe ROP is further supported by studies of Li et al. [31] and Saric et al. [32]. Studies from developing nations also have shown that decreased weight gain proportions at 4th and 6th weeks of life are risk factors for severe ROP [33, 34].

Four studies have looked at the relationship between postnatal weight gain in the first 2 weeks of life and ROP. In a prospective study by Aydemir et al. [35], the infants with severe ROP had significantly lower weight gain at 2 and 4 weeks postnatal age ($P=0.041$ and $P=0.017$ respectively) and time to regain BW was longer in infants with severe ROP ($P=0.003$). Culture proven sepsis, blood transfusion volume, days on mechanical ventilation and oxygen supplementation were significant risk factors in the severe ROP group [35]. Kim et al. [3] compared early postnatal weight gain in association with ROP needing treatment (48 preterm infants with ROP requiring treatment vs. 163 preterm infants with no ROP or ROP requiring no treatment). On univariate analysis, time to regain BW, blood transfusions and oxygen supplement days were significantly higher in the ROP needing treatment group. They also noted that relative weight gain in the second, fourth and sixth week of life was significantly lower in the group needing treatment for ROP. On logistic regression, duration of oxygen supplementation (FiO2 > 0.4) and relative weight gain in second week of life were the only significant risk factors [3]. A retrospective study by Wongnophirun et al. found that infants with severe ROP needing treatment had lower relative weight gain and total calorie intake at 2 weeks of age [36]. Vinekar A et al. [25] looked at the time to regain BW in more mature preterm neonates (mean GA = 31 ± 2 weeks) in the NICU’s (n = 68) of a developing country. The authors found that number of days to regain BW was significantly different between no ROP vs. type 1 and no ROP vs. type 2 and type 1 vs. type 2 ($P < 0.001$). A risk stratification of their data (based on number of days taken to regain BW) showed that those who regained BW less than 10 days, 11–20 days and > 20 days had low, moderate and high risk for type 1 or 2 ROP respectively [24]. In our study, time to regain BW was longer in infants who developed type 1 ROP which is similar to observations noted in studies which have looked at early postnatal weight gain and ROP [3, 25, 35].

It is important to discuss growth status at birth. We had higher number of SGA infants in Type 1 ROP group compared to controls (18.5% vs. 3.7%, $p$-value: 0.015). Studies have found inconsistent results for SGA being a risk factor for severe ROP. Filho et al. [26] and Chu et al. [37] found SGA not to be a risk factor for severe ROP, while Allegaert et al. [28] reported SGA to be a risk factor for developing threshold ROP. However, a recent systematic review and meta-analysis found SGA to be associated with increased odds for severe ROP and suggested SGA to be considered in risk assessment of ROP evaluation [38].

The limitations of this study are its retrospective nature, small sample size, lack of data on weight gain when neonates where in critical condition and weight gain after the neonate reached BW. The limitations associated with low prevalence and small sample size also limit the ability to detect differences, especially with binary outcomes. Although our result is statistically inconclusive, we cannot rule out a true effect exists in the association between time to regain birthweight and ROP.

**Conclusion**

Time to regain BW may have potential to increase the predictive ability for detecting Type 1 ROP. Phase 1 of the ROP pathogenesis corresponds to the time to regain BW. It is possible that the infants who developed Type 1 ROP were at a higher risk of low energy intake during the immediate to early postnatal period which possibly resulted in IGF-1 mediated vascularization arrest. We suggest that it is worthy to investigate our hypothesis in a larger prospective study.

**Acknowledgements**

Not applicable.

**Authors’ contributions**

AA: Literature search, data collection, study design, writing the first and final version of manuscript. EN, DD: Statistical analysis, Amendment to draft and final version of manuscript. SA, SR, AG, GL: Concept, study design, and supervision of first and final version of the manuscript. The author(s) read and approved the final manuscript.

**Funding**

No external funding was secured for this study.

**Availability of data and materials**

The data that support the findings of this study are available from the authors upon reasonable request.

**Declarations**

**Ethics approval and consent to participate**

This study was approved by King Edward Memorial hospital Governance Committee and research screening committee. Patient consent for publication not required.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1Department of Neonatal Paediatrics, Fiona Stanley hospital, Perth, Australia. 2Department of Neonatal Paediatrics, Perth Children’s Hospital, Perth, Australia. 3Department of Neonatal Paediatrics, King Edward Memorial Hospital for Women, Perth, Australia. 4Department of Paediatrics, University of Western Australia, Perth, Australia. 5Women and Infants Research Foundation, King Edward Memorial Hospital, Perth, Australia.
References

1. Husain SM, Sinha AK, Bunce C, Arora P, Lopez W, Mun KS, et al. Relationship between maternal ethnicity, gestational age, birth weight, weight gain, and severe retinopathy of prematurity. J Pediatr. 2013;163(1):67–72. https://doi.org/10.1016/j.jpeds.2012.12.038.

2. Wu C, Lofqvist C, Smith LE, DK VV, Hellstrom A. WINROP Consortium. Importance of early postnatal weight gain for normal retinal angiogenesis in very preterm infants: a multicenter study analyzing weight velocity deviations for the prediction of retinopathy of prematurity. Arch Ophthalmol. 2012;130(8):992–9. https://doi.org/10.1001/archophthalmol.2012.243.

3. Kim J, Jin JY, Kim SS. Postnatal weight gain in the first two weeks as a predictor of severe retinopathy of prematurity requiring treatment. Korean J Pediatr. 2015;58(2):52–9. https://doi.org/10.3345/kjp.2015.58.2.52.

4. Hellstrom A, Smith LE, Dammann O. Retinopathy of prematurity. Lancet. 2013;382(9902):1445–57. https://doi.org/10.1016/S0140-6736(13)60175-2.

5. Pierce EA, Foley ED, Smith LE. Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. Arch Ophthalmol. 1996;114(10):1219–28. https://doi.org/10.1001/archophthalmology.1996.0110004014019009.

6. Hellstrom A, Engstrom E, Hard AL, Albertsson-Wikland K, Carlsson B, Niklasson A, et al. Postnatal serum insulin-like growth factor I deficiency is associated with retinopathy of prematurity and other complications of prematurity birth. Pediatrics. 2003;112(5):1016–20. https://doi.org/10.1542/peds.112.5.1016.

7. Hellstrom A, Persuzzi C, Ju M, Engstrom E, Hard AL, Liu J-L, et al. Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. Proc Natl Acad Sci U S A. 2001;98(10):5804–8. https://doi.org/10.1073/pnas.101119398.

8. Hikino S, Ibara K, Yamamoto J, Takahata Y, Nakayama H, Kinukawa N, et al. Physical growth and retinopathy in preterm infants: involvement of IGF-I and GH. Pediatr Res. 2001;50(6):732–6. https://doi.org/10.1209/0003-4504-2001.12000-00017.

9. Smith LE. IGF-I and retinopathy of prematurity in the preterm infant. Biol Neonate. 2005;88(3):237–44. https://doi.org/10.1159/000108758.

10. Smith LE, Shen W, Persuzzi C, Soker S, Kinose F, Xu X, et al. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-I receptor. Nat Med. 1999;5(12):1390–5. https://doi.org/10.1038/70963.

11. Langford K, Nicolades K, Miell JP. Maternal and fetal insulin-like growth factors and their binding proteins in the second and third trimesters of human pregnancy. Hum Reprod. 1998;13(5):1389–93. https://doi.org/10.1093/humrep/13.5.1389.

12. Lassarre C, Hardouin S, Daffos F, Foretist F, Frankenne F, Binoux M. Serum insulin-like growth factors and insulin-like growth factor binding proteins in the human fetus. Relationships with growth in normal subjects and in subjects with intrauterine growth retardation. Pediatr Res. 1991;29(3):219–25. https://doi.org/10.1203/00006450-199103000-00001.

13. Lineham JD, Smith RM, Dahlenburg GW, King RA, Haslam RR, et al. Circulating insulin-like growth factor-I levels in newborn prematures and full-term infants followed longitudinally. Early Hum Dev. 1986;13(1):37–46. https://doi.org/10.1016/0378-3782(86)90096-4.

14. Engstrom E, Niklasson A, Wilkand KA, Ewald U, Hellstrom A. The role of maternal factors, postnatal nutrition, weight gain, and gender in regulation of serum IGF-I among preterm infants. Pediatr Res. 2005;57(4):605–10. https://doi.org/10.1203/01.PDR.0000159590.67503.BC.

15. Birnbaum G. Algorithms for the prediction of retinopathy of prematurity based on postnatal weight gain. Clin Perinatol. 2013;40(2):261–70. https://doi.org/10.1016/j.clp.2013.02.004.

16. Lee JW, McBrath T, Chen M, Wallace DK, Allred EN, Leviton A, et al. Pregnancy disorders appear to modify the risk for retinopathy of prematurity associated with neonatal hyperoxemia and bacteremia. J Matern Fetal Neonatal Med. 2013;26(8):811–18. https://doi.org/10.3109/14767058.2013.764407.

17. Austeng D, Kallen KB, Ewald UW, Jakobsson PG, Holmstrom GE. Incidence of retinopathy of prematurity in infants born before 27 weeks’ gestation in Sweden. Arch Ophthalmol. 2009;127(10):1315–9. https://doi.org/10.1001/archophthalmol.2009.244.

18. Darlow BA, Hutchinson JL, Henderson-Smart DJ, Donoghue DA, Simpson JM, Evans NJ. Australian and New Zealand neonatal network. Prenatal risk factors for severe retinopathy of prematurity among very preterm infants of the Australian and New Zealand neonatal network. Pediatrics. 2005;115(6):990–6. https://doi.org/10.1542/peds.2004-1309.

19. Lofqvist C, Andersson E, Sigurdsson J, Engstrom E, Hard AL, Niklasson A, et al. Longitudinal postnatal weight and insulin-like growth factor I measurements in the prediction of retinopathy of prematurity. Arch Ophthalmol. 2006;124(12):1711–8. https://doi.org/10.1001/archopht.2006.124.12.1711.

20. Fortes Filho JB, Bonomo PP, Maia M, Procyanow RS. Weight gain measured at 6 weeks after birth as a predictor for the development of retinopathy of prematurity. J Matern Fetal Neonatal Med. 2019;32(3):429–33. https://doi.org/10.1080/14767058.2017.1381902.

21. Early Treatment For Retinopathy Of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol. 2003;121(12):1684–94. https://doi.org/10.1001/archopht.121.12.1684.

22. Fierson WM. American Academy of Pediatrics section on ophthalmology; American Academy of ophthalmology; American Association for Pediatric Ophthalmology and Strabismus; American Association of Certified Orthoptists. Screening examination of premature infants for retinopathy of prematurity. Pediatrics. 2018;142(6):e20183061.

23. Early postnatal weight gain as a predictor for the development of retinopathy of prematurity. J Matern Fetal Neonatal Med. 2019;32(3):429–33. https://doi.org/10.1080/14767058.2017.1381902.

24. Early Treatment For Retinopathy Of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol. 2003;121(12):1684–94. https://doi.org/10.1001/archophthalmology.121.12.1684.

25. Fortes Filho JB, Valiati FB, Eckert GU, Costa MC, Silveira RC, Procyanow RS. Is being small for gestational age a risk factor for retinopathy of prematurity? A study with 345 very low birth weight preterm babies. J Pediatr (Rio J). 2009;85(1):48–54. English, Portuguese. https://doi.org/10.2223/JPED.1870.

26. Fortes Filho JB, Klysstra JA, Phillips SJ, Hall JG. Poor postnatal weight gain: a risk factor for severe retinopathy of prematurity. J AAP. 2000;4(6):343–7. https://doi.org/10.1067/mepa.2000.110342.

27. Allegraert K, Vanhoke C, Castells I, Naulaers G, Debeer A, Cossy V, et al. Perinatal growth characteristics and associated risk of developing threshold retinopathy of prematurity. J AAP. 2003;71(1):34–7. https://doi.org/10.1067/mapi.2003.51091851012240159.

28. Cabanas-Poy MJ, Montoro-Ronsano JB, Castillo-Salinas F, Martín-Begue N, Clemente-Bautista S, Gorgas-Torner MQ. Association between postnatal weight gain and insulin-like growth factor I. Arch Ophthalmol. 2009;127(10):1315–9. https://doi.org/10.1001/archophthalmol.2009.244.

29. Chaves-Samaniego MJ, Chaves-Samaniego MC, Munoz Hoyos A, Garcia Sierrajo NL. New evidence on the protector effect of weight gain in retinopathy of prematurity. An Pediatr (Engl Ed). 2021;95(2):78–85. https://doi.org/10.1016/j.anpede.2020.05.016.
31. Li Y, Shah M, Miller MR, Lee DSC, Sharan S. Impact of early postnatal weight gain on retinopathy of prematurity in very preterm infants in southwestern Ontario. J Pediatr Ophthalmol Strabismus. 2019;56(3):168–72. https://doi.org/10.3928/01913913-20190208-01.

32. Behin Saric I, Saric MJ, Vukojevic N. Poor postnatal weight gain as a predictor of retinopathy of prematurity. Acta Clin Croat. 2020;59(3):407–15. https://doi.org/10.20471/acc.2020.59.03.03.

33. Aydemir O, Sarikabadayi YU, Aydemir C, Tunay ZO, Tok L, Erdeve O, et al. Adjusted poor weight gain for birth weight and gestational age as a predictor of severeROP in VLBW infants. Eye (Lond). 2011;25(6):725–9. https://doi.org/10.1038/eye.2011.29.

34. Wang ZH, Gao PF, Bai H, Li YY. Postnatal weight gain in very low birth weight infants in Beijing and the risk of retinopathy of prematurity. Int J Ophthalmol. 2015;8(6):1207–10. https://doi.org/10.3980/j.issn.2222-3959.2015.06.23.

35. Anuk Ince D, Gulcan H, Hanta D, Ecevit A, Akkoynun I, Kurt A, et al. Poor postnatal weight gain predicts stage 3+ retinopathy of prematurity in very low birth weight infants. Turk J Pediatr. 2013;55(3):304–8.

36. Wongnophirun A, Khwuthyakorn V, Tantiprabha W, Wiwatwongwana A. Association between severe retinopathy of prematurity and postnatal weight gain in very low-birthweight infants at Chiang Mai University Hospital, Thailand. Paediatr Int Child Health. 2020;40(2):85–91. https://doi.org/10.1080/20469047.2019.1631588.

37. Chu A, Dhindsa Y, Sim MS, Ahtendahl M, Tsui J. Prenatal intrauterine growth restriction and risk of retinopathy of prematurity. Sci Rep. 2020;10(1):17591. https://doi.org/10.1038/s41598-020-74600-0.

38. Razak A, Faden M. Association of small for gestational age with retinopathy of prematurity: a systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed. 2020;105(3):270–8. https://doi.org/10.1136/archdischild-2019-316976.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.